Biotech Startups

Mirvie develops an RNA-based platform for early detection of pregnancy complications, enabling proactive intervention before complications become critical. The platform serves pregnant women and their healthcare providers to improve maternal and fetal health outcomes.

7 investors

Modicus Prime provides an AI Management System (AIMS) for pharmaceutical companies and contract development and manufacturing organizations (CDMOs) to validate, audit, and govern AI systems across their operations in compliance with FDA and other regulatory requirements.

7 investors

Modulo is a biotech company focused on the neuroimmune system, developing treatments for brain and central nervous system disorders. It uses multiple neurobiology models and computational biology to study neuroimmune mechanisms and discover new therapies for patients affected by neurological disease.

7 investors

MycoWorks produces Reishi, a premium biomaterial made from Fine Mycelium, used as a sustainable leather alternative in furniture, design, and automotive products. The company works with designers, studios, and brands such as Ligne Roset and Cadillac to create finished goods.

7 investors

Developer of microfluidic cell sorting technologies for the biotech industry.

7 investors

Neopenda develops health-technology devices for neonatal care in emerging markets, specifically serving healthcare facilities in underserved populations. The company, structured as a public benefit corporation, focuses on innovative products to improve health outcomes in resource-limited settings.

7 investors

Neumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.

7 investors

NeuraLight develops AI-powered digital biomarkers for neurological diseases including Alzheimer's, Parkinson's, and multiple sclerosis. The company uses signal processing and computer vision to enable clinical assessment and disease monitoring for healthcare providers and medical institutions.

7 investors

Neuspera Medical develops an integrated sacral neuromodulation (iSNM) system that implants a smart neurostimulator near the sacral nerve to treat urinary urge incontinence, a symptom of overactive bladder. Its device is powered by a discreet, wirelessly charged external battery worn daily, targeting patients—particularly women in the U.S.—affected by these conditions.

7 investors

Nix develops wearable biosensors that measure health metrics like hydration in real-time for athletes, soldiers, and laborers outside traditional healthcare settings. The company's first product is a hydration biosensor designed to optimize safety and performance monitoring.

7 investors

Nomic offers an end-to-end protein profiling service built on its nELISA technology, quantifying up to 1000 informative proteins with absolute quantification for research studies. It targets researchers doing proteomics work, aiming for high-throughput, low-cost profiling in the biotech and life sciences market.

7 investors

Numerion Labs develops machine learning algorithms for drug discovery, combining computational chemistry, structural biology, and medicinal chemistry. It builds AI-driven platforms aimed at accelerating the identification of new medicines.

7 investors

Nurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases. The company applies targeted protein degradation to overcome limitations of conventional therapeutic approaches.

7 investors

OneSkin develops skincare products based on its OS-01 Peptide, an ingredient the company says targets cellular senescence to address signs of skin aging. Founded by scientists, it positions its products within the longevity and skin-health consumer market.

7 investors

ONL Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve sight by preventing Fas-mediated death of retinal cells, a cause of vision loss and blindness. Its lead candidate, xelafaslatide (formerly ONL1204), is a first-in-class small peptide targeting Fas-mediated signaling across multiple eye diseases.

7 investors

Orchid offers whole genome sequencing-based genetic screening of embryos during IVF as well as preconception testing for couples, analyzing DNA to identify predispositions to monogenic diseases, chromosomal abnormalities, and polygenic risks. It serves prospective parents and IVF patients, delivering reports reviewed by board-certified genetic counselors.

7 investors

PACT develops earth-positive biomaterials for the fashion industry, scaling them up for supply to partner brands. The company runs a research and development laboratory and pilot facilities where scientists, engineers and designers create sustainable materials.

7 investors

PATH EX develops CycloPE, an extracorporeal blood purification device that removes bacteria from the bloodstream to treat sepsis in critically ill patients. The technology is designed to integrate with existing ICU workflows and can be used before pathogen identification, targeting both drug-susceptible and drug-resistant bacteria.

7 investors

Persephone Biosciences develops live biotherapeutic products that modulate the metabolism of gut microbes for disease prevention and treatment, with a focus on cancer. It applies systems and synthetic biology to study the gut microbiome.

7 investors

Persist AI provides AI-driven formulation development services for pharmaceutical compounds, combining robotic lab automation with machine learning models to accelerate drug formulation optimization and reduce time-to-market.

7 investors

Phantom Neuro develops neurotechnology for human-machine interaction, with a focus on applications for limb-loss and amputee populations. The company works in the neurotech and medical device space, drawing on neuroscience, robotics, and human performance research.

7 investors

Plastomics develops trait delivery technology for agriculture using cell biology, plant tissue culture, transformation, and molecular biology methods. The company serves the agricultural industry with next-generation biotechnology solutions.

7 investors

Prellis Biologics runs an antibody discovery platform that uses two-photon laser-bioprinted human immune organoids combined with machine learning to identify fully human antibody therapeutics. It develops a portfolio of antibody drug candidates across multiple disease areas and partners with biotech and pharmaceutical companies.

7 investors

Pretzel Therapeutics develops therapeutics targeting bioenergetic dysfunction and mitochondrial disease by addressing defects in mitochondrial DNA function and gene expression. The company leverages expertise in mitochondrial biology and drug discovery to create treatments for diseases associated with mitochondrial dysregulation.

7 investors